title: Efficacy of Nab-Paclitaxel as Second-line Chemotherapy for Unresectable or Recurrent Gastric Cancer.
abstract: To evaluate the efficacy and safety of nanoparticle albumin-bound-paclitaxel (nab-PTX) as second-line chemotherapy (CT) for patients with unresectable or recurrent gastric cancer (GC).
  
  
  
  The clinicopathological and survival data of 37 patients with unresectable or recurrent GC who underwent nab-PTX monotherapy as second-line CT, were retrospectively analyzed.
  
  
  
  The median number of cycles and relative dose intensity administered per patient were 5 and 90%, respectively. Their overall response rate was 24.3% and the disease control rate was 59.5%. Median progression-free survival (PFS) and overall survival were 4.8 months and 10.4 months, respectively. Thirteen patients had grade 3 or 4 toxicities and were managed. In multivariate Cox regression analysis, cycles of chemotherapy ≥5 (odds ratio, 0.20; 95% confidence interval, 0.08-0.50; p<0.01) was the only significant independent predictor of longer PFS.
  
  
  
  Nab-PTX may effectively prevent disease progression as second-line CT by increasing treatment cycles and managing adverse effects.
authors.affiliation: Department of Digestive Tract and General Surgery, Saitama Medical University, Kawagoe, Japan mfukuchi@saitama-med.ac.jp.
authors.forename: Minoru
authors.initials: M
authors.lastname: Fukuchi
authors.affiliation: Department of Digestive Tract and General Surgery, Saitama Medical University, Kawagoe, Japan.
authors.forename: Erito
authors.initials: E
authors.lastname: Mochiki
authors.affiliation: Department of Digestive Tract and General Surgery, Saitama Medical University, Kawagoe, Japan.
authors.forename: Toru
authors.initials: T
authors.lastname: Ishiguro
authors.affiliation: Department of Digestive Tract and General Surgery, Saitama Medical University, Kawagoe, Japan.
authors.forename: Toshiro
authors.initials: T
authors.lastname: Ogura
authors.affiliation: Department of Digestive Tract and General Surgery, Saitama Medical University, Kawagoe, Japan.
authors.forename: Jun
authors.initials: J
authors.lastname: Sobajima
authors.affiliation: Department of Digestive Tract and General Surgery, Saitama Medical University, Kawagoe, Japan.
authors.forename: Youichi
authors.initials: Y
authors.lastname: Kumagai
authors.affiliation: Department of Digestive Tract and General Surgery, Saitama Medical University, Kawagoe, Japan.
authors.forename: Keiichiro
authors.initials: K
authors.lastname: Ishibashi
authors.affiliation: Department of Digestive Tract and General Surgery, Saitama Medical University, Kawagoe, Japan.
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Ishida
mesh_terms: D000368:Aged; D000418:Albumins / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000627:therapeutic use*; D013274:Stomach Neoplasms / Q000188:drug therapy*; D015996:Survival Rate
chemical_list: C520255:130-nm albumin-bound paclitaxel; D000418:Albumins; D000970:Antineoplastic Agents; D017239:Paclitaxel
keywords: Gastric cancer; nab-paclitaxel; progression-free survival; second-line chemotherapy